«According to IQVIA, Russia is home to more than 900 manufacturers (92 companies with revenue of more than USD 15 million in 2021). RNC Pharma found that 76.7% of raw materials imported to Russia in 2021 came from India and China and 19.7% came from EU countries. Russia imported a total of 15,800 tonnes of pharmaceutical substances worth RUB 195.4 billion last year». The countrys import substitution agenda has taken on increased importance due to the challenges of 2022. Russia must become independent of imported medicines, medical devices, and equipment. Long-term solutions need to found as soon as possible in order to build logistics tracks, replace imported raw materials in manufacturing, and prevent a shortage of high-quality components and vital medical products. To saturate the Russian market, it is essential to accelerate the introduction of domestic developments, provide financial support, and establish technological chains at all stages of production, from the procurement of raw materials to the production of a final product that is competitive compared with world analogues. What state support measures for key enterprises in the pharmaceutical and medical industries, product distributors, and pharmacy chains envisage the development of the Russian pharmaceutical industry? Can Russian production facilities provide high-precision equipment to the market? What measures to support small and medium-sized pharmaceutical businesses could contribute to the development of the pharmaceutical market? What risks exist after the timeframe for the state registration and expert examination of the quality of medicines is shortened?